The past years MDxHealth had a huge negative momentum. The stock made the past 5 years a huge loss of 38 percent. With that the stock belongs to the worst shares of the biotech companies. The sector yielded the past 5 years a gain of at around 243 percent. Other shares with huge negative returns in the peer group are Akers Biosciences, Galena Biopharma and Alliqua BioMedical. Akers Biosciences, Galena Biopharma and Alliqua BioMedical are among the losers in the sector.
Returns stock MDxHealth over several periods, excluding dividend returns
Investors who invested in 2007 in the company's share now have a huge loss of 72 percent. Since 2012 the stock has a loss of 38 percent. over the past 90 days the stock made a profit of 5 percent.
For the average share in the sector around 4 times the earnings per share is paid. Currently the sector trades at 2,28 times the book value per share. Since 2012 the sector is 243 percent higher and since 2007 432 percent higher.
For this year MDxHealth's revenue will be around 36,96 million euros. This is according to the average of the analysts' estimates. This is slightly lower than 2017's revenue of 40,51 million euros.
The analysts expect for 2018 a net loss of 21 million euros. According to most of the analysts the company will have a loss per share for this book year of 45 cent. Based on this the price/earnings-ratio is -4,04.
For this year analysts don't expect the company to pay a dividend. The average dividend yield of the biotech companies equals a limited 0,5 percent.
Based on the current number of outstanding shares MDxHealth's market capitalization 90,72 million euros. The MDxHealth stock was the past 12 months quite unstable. Since last January the stock is 43 percent lower. This year the stock price moved between 1 and 4 euro. Since 2008 the stock price is almost 72 percent lower.
On Friday the stock closed at 1,82 euros.
ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
news@valuespectrum.com
Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.